Efficacy and Safety of Infliximab in HLA-B27-associated Ocular Inflammation Refractory or Intolerant to Conventional Immunomodulatory Therapy

Asima Bajwa, MD1,3, Arash Maleki, MD1,3, Abhishek R Payal, MD1,3,4, Adriana Fandiño, MD1,3
María Inés Menéndez Padrón, MD1,3, Marisa Walsh, BS1,3, C Stephen Foster, MD, FACR, FACS1,2,3
1Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts
2Harvard Medical School, Boston, Massachusetts
3Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts
4University of Pennsylvania, Scheie Eye Institute, Philadelphia, Pennsylvania

ORCID:
Asima Bajwa: https://orcid.org/0000-0002-5823-3312
Arash Maleki: https://orcid.org/0000-0001-5533-9798
Charles Stephen Foster: https://orcid.org/0000-0003-4760-8390

Abstract

Purpose: To determine the efficacy and safety of infliximab therapy in patients with HLA B-27-associated ocular inflammation resistant or intolerant to conventional immunomodulatory therapy.

Methods: This was a retrospective observational case series. All cases were uveitic patients with positive HLA-B27, confirmed through HLA testing, resistant or intolerant to conventional immunomodulatory therapy. The primary outcome of the study was to identify the efficacy of infliximab determined by the control of inflammation, duration of remission, and the ability to reduce conventional immunomodulatory therapy. The secondary outcome was an improvement of two or more lines of best-corrected visual acuity (BCVA) on the Snellen visual acuity chart.

Results: Twenty-four patients (38 eyes) were included in the study. All patients were followed for 24 months. Twenty-one (87.5%) patients completed 24 months of follow-up. Sixteen (66.7%) patients had active uveitis at the beginning of therapy. One patient out of these active patients had active inflammation at the end of follow-up period. Thirteen (87.5%) out of sixteen active patients were in steroid-free remission. The mean duration of treatment to induce remission was 16.5 months (range 6–24 months). Corticosteroid was stopped in 19 (90.5%) patients by the end of the study. At the end of the study, in patients who achieved remission, 14 (58.3%) patients were in remission on infliximab therapy and 6 (25%) patients were in remission off infliximab therapy. Of the 38 eyes, 8 (21.05%) showed improvement in BCVA (three eyes had successful cataract extraction with intraocular lens implantation during infliximab therapy with no subsequent inflammation), while 26 eyes (68.4%) had stable BCVA over the 24-month study period. The side effects included allergic reaction, fatigue, cellulitis, headache, restlessness, elevation of liver enzymes, and anemia. Two patients (n = 24, 8.3%) experienced severe adverse effects and the treatment was stopped prematurely in these two patients.

Conclusion: Infliximab might induce and maintain the steroid-free remission in HLA-B27-associated ocular inflammation in patients resistant or intolerant to conventional immunomodulatory therapy.

Keywords: HLA-B27; Immunomodulatory Therapy; Infliximab; TNF-α; Uveitis; Vasculitis

J Ophthalmic Vis Res 2020; 15 (4): 459–469
INTRODUCTION

Acute anterior uveitis (AAU) is the most common form of intraocular inflammatory disease and can be associated with the human leukocyte antigen (HLA)-B27 haplotype in approximately 55–71% of patients.[1,2] It usually manifests at a young age as recurrent, acute, non-granulomatous uveitis, with a unilateral or alternating bilateral presentation. The disease may involve posterior segment in the form of optic disc edema, macular edema, choroidal folds and effusions, exudative retinal detachment, and anterior and posterior scleritis.[3]

Intense inflammation and protein coagulum in the aqueous may lead to temporary or permanent severe visual impairment.

Topical corticosteroids, the first line of therapy, are sometimes insufficient to control the intraocular inflammation. Additional periocular and/or systemic corticosteroids and sometimes both are required to control the inflammation in more severe cases. Corticosteroid treatment increases the risk of systemic and ocular complications such as glaucoma and cataract. Therefore, corticosteroid-sparing conventional immunomodulatory therapies such as methotrexate, azathioprine, and mycophenolate mofetil (MMF) have been employed in the treatment of these patients. Biologic response modifier agents are the next step of the step ladder approach in the treatment of patients intolerant or resistant to conventional immunomodulatory therapy (IMT).[4,5]

Infliximab is a mouse–human chimeric immunoglobulin G1 (IgG1) monoclonal antibody that binds both the soluble and the membrane-bound precursor of tumor necrosis factor-alpha (TNF-α) and acts as a TNF-α inhibitor. It has been employed off-label in the treatment of non-infectious ocular inflammatory diseases refractory to conventional IMT with a high rate of inflammation control and few adverse effects.[6–14]

There are very few studies which have specifically focused on the HLA B-27-associated ocular inflammation.[12,13] Even fewer studies have evaluated the efficacy and safety of infliximab therapy in patients with HLA-B27-associated ocular inflammation resistant or intolerant to conventional IMT.[15] In this study, the efficacy and safety of steroid-free infliximab therapy were assessed in an HLA-B27 positive ocular inflammatory diseases in patients resistant or intolerant to conventional IMT.

METHODS

This study was a single-center retrospective observational case series. Approval for this study was obtained through the New England Institutional Review Board, which issued a waiver of informed consent, as this was a retrospective chart review analysis. This study was performed in accordance with the Declaration of Helsinki and was HIPAA compliant.

Electronic charts of patients with HLA-B27-associated ocular inflammation and infliximab (Remicade; Centocor, Inc, Malvern, Pennsylvania) therapy between July 2005 and October 2012 were examined. Those patients who received infliximab as the primary treatment were excluded.

Twenty-four patients (38 eyes) who had received at least one conventional IMT and/or another biologic response modifier agent were included in the study. The baseline demographic data, clinical diagnosis, and previous treatments were extracted from the charts. The best-corrected visual acuity (BCVA), slit lamp biomicroscopy, funduscopy positive findings, and intraocular pressure prior to and at 3, 6, 9, 12, 18, 24 months after starting the infliximab therapy were collected. Flare-ups, dose, and frequency of infliximab infusions, duration of follow-up, and severe adverse effects of infliximab were noted. Severe adverse effects were described as a severe side effect significant enough for the termination of infliximab therapy.
Standardization of Uveitis Nomenclature (SUN) Working Group grading scheme was used for the assessment of anterior chamber cell and flare.\[^{15}\] Cases seen prior to the publication of SUN guidelines were reclassified following the new anatomical classification system. Inactive anterior uveitis was defined as less than one plus cells in anterior chamber and inactive vitreous inflammation was defined as less than one plus vitreous haze.\[^{15, 16}\] Inactive scleritis was defined based on Sen et al’s study.\[^{17}\]

In this study, refractory ocular inflammation was described as unresponsive inflammation or intolerance to a three-month course of treatment with at least two different conventional immunomodulatory agents.

Patients without inflammation for the consecutive six months of infliximab therapy were categorized as “remission on treatment” group. The “remission off treatment” group was defined as inflammation-free for a period of six consecutive months without infliximab treatment.

All patients had blood tests, which included a complete blood cell count (CBC), liver function tests (LFTs), and renal function tests before each infusion. They also had purified protein derivative skin test or QuantiFERON blood test, and anti-nuclear antibody (ANA) once at baseline and yearly afterward.

All patients received a loading dose of 5 mg/kg at 0 and 2 weeks, then every 4 weeks for five more infusions. However, some patients received higher doses of infliximab such as 7.5 mg/kg then 10 mg/kg after the third infusion because of the presence of inflammation in the complete ocular examination and/or ancillary tests. After six months, the frequency of infusions was stretched gradually from 6 to 12 weeks based on the response to the treatment and the absence of the active inflammation. The treatment was stopped once the patient was stable at the 12-week infliximab infusion intervals for four consecutive infusions.

In this study, the side effects were defined as adverse effects severe enough to justify the treatment termination. All patients responded to a questionnaire and the blood sample was collected to evaluate for possible medication toxicity in white blood cell (WBC), red blood cell (RBC), platelet (PLT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALKP), gamma glutamine transferase (GGT), blood urea nitrogen (BUN), and creatinine (Cr) before each infusion.

The primary outcome of the study was to determine the efficacy of infliximab determined by the control of inflammation, duration of remission, and the ability to reduce conventional IMT. The safety of the study was defined as the absence of severe side effects. The secondary outcome was an improvement of two or more lines of BCVA on the Snellen acuity chart.

**Statistical Analysis**

Data were presented as descriptive statistics (mean, percentages, range). Microsoft Excel 2010 (Microsoft, Richmond, VA) was used for statistical analysis. Paired and unpaired two-tailed t-tests were used to compare the number of medications, intraocular pressure, and visual acuity changes before and after the treatment. The level of significance was set at \( P \leq 0.05 \).

**RESULTS**

Twenty-four patients (38 eyes) were included in the study. The average age of the patients was 44.7 ± 13.6 (12–67 years). Of the 24 patients, 14 (58.3%) were women and 14 (58.3%) had bilateral involvement. The prevalence of one or more associated systemic illness including ankylosing spondylitis, reactive arthritis, inflammatory bowel disease, psoriatic arthritis, and juvenile rheumatoid arthritis was 70.8% (17 of 24) (Table 1). Sixteen patients (\( n = 24, 66.7\% \)) at baseline had active ocular inflammation, which was reduced to only one patient (\( n = 21, 4.7\% \)) at the 24-month follow-up visit (Table 2). Of the sixteen patients with active ocular inflammation at baseline, 6 patients (37.5%) and 10 eyes (38.5%) had chronic inflammation, while the other 10 patients (62.5%) and 16 eyes (61.5%) were diagnosed with an acute flare up. All patients were on at least one conventional IMT and/or another biologic response modifier agent (Table 3).

The infliximab therapy was prematurely stopped in three patients (12.5%) between the three- and six months follow-up period due to one patient with a severe allergic reaction (itching, rash, and shortness of breath during the infusion), one patient with a significant rise in liver enzymes (ALT and AST more than 10 times of the normal), and one patient with a significant rise in liver enzymes (ALT and AST more than 10 times of the normal), and one
Table 1. General characteristics and medication

| Characteristics                   | Value                      |
|-----------------------------------|----------------------------|
| Age – yr                          | Mean ± SD 44.7 ± 13.6       |
|                                   | Range 12–67                |
| Female – no. (%)                  | 14 (58.3)                  |
| Systemic Diseases† – no. (%)      | 17 (70.8)                  |
| AS                                | 9 (37.5)                   |
| AS and RA                         | 2 (8.3)                    |
| AS and IBD                        | 1 (4.1)                    |
| PA                                | 2 (8.3)                    |
| NSA                               | 2 (8.3)                    |
| JIA                               | 1 (4.2)                    |

Conventional therapy

| Before infliximab patients (n = 24) (%) | After infliximab patients (n = 24) (%) |
|----------------------------------------|----------------------------------------|
| Corticosteroids (by route)             |                                       |
| None                                   | 0 (0)                                  |
| Topical                                | 21 (87.5)                              |
| Periocular and/or intraocular¶         | 8 (33.3)                               |
| Oral and/or intravenous                | 13 (38.1)                              |
| IMT (by number of medications)‡        |                                       |
| None                                   | 0 (0)                                  |
| 1 medication                           | 7 (29.2)                               |
| 2 medications                         | 8 (33.3)                               |
| ≥3 medications                        | 9 (37.5)                               |
| Side effects after infliximab (n = 24) |                                       |
| Allergic reaction                     | –                                      |
| Fatigue                                | –                                      |
| Cellulitis                             | –                                      |
| Headache, restlessness                 | –                                      |
| AST/ALT elevation                      | –                                      |
| Anemia                                 | –                                      |

†AS, ankylosing spondylitis; RA, reactive arthritis; IBD, inflammatory bowel disease; PA, psoriatic arthritis; NSA, nonspecific arthritis; JIA, juvenile inflammatory arthritis
¶At least one month before infliximab therapy
‡IMT, Immunomodulatory therapy
AST, aspartate aminotransferase; ALT, alanine aminotransferase

Of the eight inactive patients (33.3%) at baseline, six patients (25%) were started on infliximab treatment due to intolerance to previous conventional IMT therapy. In the other two patients (8.3%), infliximab was started for an active systemic disease by their rheumatologist. The latter two developed an ocular inflammation during the first three months of follow-up.

For the patients with active disease at baseline, the duration of the treatment required to induce remission varied from less than six months in four (n = 16, 25%) patients to more than one year in five (n = 16, 31.3%) patients. Six patients (n = 16, 37.5%) were in remission by the second
Table 2. Inflammation status before and after the infliximab therapy excluding inactive patients

| Ocular inflammation | Before Infliximab [patients (%)] (n = 16) | After Infliximab [patients (%)] (n = 16) |
|---------------------|------------------------------------------|------------------------------------------|
|                     | 3 months       | 6 months       | 12 months      | 18 months      | 24 months      |
| Active              | 16 (100)       | 3 (16.6)       | 2 (12.5)       | 2 (12.5)       | 2 (12.5)       | 1 (6.25)       |
| Anterior uveitis    | 11 (68.7)      | 1 (6.25)       | –              | –              | 1 (6.25)       | –              |
| Scleritis           | 2 (12.5)       | –              | –              | –              | –              | –              |
| Vitritis            | 1 (6.25)       | –              | –              | –              | –              | –              |
| Retinal vasculitis  | –              | 1 (6.25)       | 1 (6.25)       | 1 (6.25)       | 1 (6.25)       | 1 (6.25)       |
| Anterior uveitis with retinal vasculitis | – | – | 1 (6.25) | – | – | – |
| Vitritis with retinal vasculitis | 1 (6.25) | – | – | 1 (6.25) | – | – |
| Papillitis with retinal vasculitis | – | 1 (6.25) | – | – | – | – |
| Vitritis, papillitis, and retinal vasculitis | 1 (6.25) | – | – | – | – | – |

Table 3. Immunomodulatory therapy before starting the infliximab therapy in patients with HLA-B27 ocular inflammation

| Immunomodulatory therapy | Number (%) |
|--------------------------|------------|
| Methotrexate             | 10 (41.6%) |
| Mycophenolate Mofetil    | 5 (20.8%)  |
| Humira                   | 5 (20.8%)  |
| Cyclosporine             | 2 (8.33%)  |
| Chlorambucil             | 1 (4.16%)  |
| Daclizumab               | 1 (4.16%)  |
| Etanercept               | 1 (4.16%)  |
| Azathioprine             | 1 (4.16%)  |
| Celecoxib                | 1 (4.16%)  |
| None                     | 4 (16.6%)  |

year of the follow-up period. At the end of the study, 14 (58.3%) patients were in remission on infliximab therapy and six (25%) were in remission off infliximab therapy (Figure 2). The mean duration between starting the treatment and induction of remission was 16.5 months (range, 3–24 months). Table 4 demonstrates how patients with flare up were treated during the study period.

Before employing infliximab therapy, all patients had received one or more routes of corticosteroid administration, including topical, periocular, systemic therapy based on the severity of the disease. Twenty-one patients (87.5%) were receiving topical corticosteroids; six patients (37.5%), two patients (8.33%), and another two patients (8.33%) received transseptal, intravenous, and intravitreal corticosteroids, respectively. Eleven patients (45.8%) were on oral prednisone; higher doses (30–60 mg) were employed in four patients (16.7%) with severe active inflammation. Seven patients (29.1%) were on maintenance oral prednisone therapy with an average dose of 8.7 mg (range, 7–10). Nineteen patients (90.5%) discontinued corticosteroids by the end of the study. At the 24-month follow-up, 13 patients (87.5%) out of the 16 active patients were in steroid-free remission. During the 24 months of follow-up, the number of conventional IMT agents were reduced in 14 (58.3%) patients, the dosage of medications was halved in two patients (8.3%), and medications were discontinued in five (n = 21, 23.8%) patients (Table 1). The average number of medications before starting treatment was 2.3 ± 1.14 and at the end of the follow-up period was
### Table 4. Management of patients with ocular inflammation flare-up during the study period

| Study period | Number of patients with flare-up of ocular inflammation | Treatment for flare-up |
|--------------|----------------------------------------------------------|------------------------|
| 3-6 months   | 4 (17.4%, n = 23)                                        | 3 patients (n = 23, 13%) – reducing the infliximab infusion interval  
              |                                                          | 1 patient (n = 23, 4.3%) – boosting infliximab dose  
              |                                                          | 1 patient (n = 23, 4.3%) with persistent vasculitis – MMF and CSA were substituted for methotrexate and adalimumab |
| 6–12 months  | 4 (19%, n = 21)                                          | 1 patient (n = 21, 4.8%) with papillitis, vitritis, and retinal vasculitis – received additional intravenous pulse steroids and was switched to cyclophosphamide  
              |                                                          | 2 patients (n = 21, 9.5%) – received increased dose of infliximab  
              |                                                          | 1 patient (n = 21, 4.8%) with retinal vasculitis – received increased doses of infliximab along with MMF and CSA |
| 12–18 months | 2 (9.5%, n = 21)                                         | 1 patient (n = 21, 4.8%) with persistent retinal vasculitis – received increased dose of infliximab along with oral corticosteroids  
              |                                                          | 1 patients (n = 21, 4.8%) – relapsed with anterior uveitis and was restarted on infliximab |
| 18–24 months | 3 (14.3%, n = 21)                                        | 1 patient (n = 21, 4.8%) – added methotrexate  
              |                                                          | 1 patient (n = 21, 4.8%) – reducing interval and boosting dose of infliximab  
              |                                                          | 1 patient (n = 21, 4.8%) – increasing the dose of infliximab with oral steroids |

MMF, mycophenolate mofetil; CSA, Cyclosporin-A

**Figure 1.** The number of patients in total, with active and inactive disease at each follow-up visits.
0.08 ± 0.2. The difference in the average number of medications before starting the treatment and at the end of the study period was statistically significant ($P < 0.0001$).

Of the 38 eyes, 8 eyes (21.05%) showed improvement in BCVA (three eyes had cataract extraction with intraocular lens implantation during infliximab therapy with no subsequent eye inflammation), while 26 eyes (68.4%) had stable BCVA over the 24-month study period. The mean visual acuity before starting infliximab treatment was 20/30–20/40 (0.22 ± 0.43 LogMAR) and was 20/25 (0.1 ± 0.24 LogMAR) after the treatment. The mean difference of visual acuity before starting infliximab therapy and at the end of 24 months of follow-up was not statistically significant ($P = 0.14$). Moreover, the changes in visual acuity in each eye before starting the treatment and at the last follow-up visit were not statistically significant ($P = 0.06$).

The average intraocular pressure in all uveitic eyes of patients before starting infliximab therapy was 16.3 ± 4.56 mmHg (10–34). The averages of intraocular pressure in the worse and better eyes of patients were 18.2 ± 4.61 mmHg and 14.5 ± 3.44 mmHg, respectively. At the last follow-up visit, the average of intraocular pressure in all uveitic eyes of patients was 14.9 ± 2.00 mmHg (10–20). Averages of intraocular pressure in the worse eyes and better eyes of patients were 14.9 ± 2.07 and 14.57 ± 2.2 mmHg, respectively. Using the paired t-test, the difference between the intraocular pressure of the worse eye of each patient before starting the treatment and at the last follow-up was statistically significant ($P = 0.004$); however, this difference was not significant in the better involved eyes of each patient ($P = 0.8$).

The primary dose of infliximab was 5 mg/kg body in 19 patients. In three patients (12.5%), infliximab was started at the highest dose of 10 mg/kg: one patient was monocular, one had severe scleritis, and one had extensive retinal vasculitis.

The side effects included allergic reaction, fatigue, cellulitis, headache, restlessness, elevation of liver enzymes, and anemia. The treatment was discontinued in three (12.5%) patients; two due to the development of side effects and one due to insurance problems. These three patients were considered as treatment failures.

**DISCUSSION**

The association between HLA-B27 positivity and AAU with or without a spectrum of other inflammatory diseases was originally described in 1973 and is one of the strongest HLA-disease associations.\[18,19\] TNF-α gene controls the production of TNF-α, which is a cytokine...
and inflammatory mediator in animal models of uveitis. TNF-α has been detected in the uvea and retina at the early stages of acute uveitis. In addition, TNF-α has been found in higher levels in the sera and aqueous humor of patients with uveitis.\cite{5,20} It may induce expression of chemokines, adhesion molecules, and other proinflammatory cytokines causing protracted inflammatory process.\cite{21} Its blockade is associated with decreased ocular inflammation in animal models.\cite{22–24} Sahrawi et al proposed that HLA B27-positive individuals show a higher susceptibility toward development of intraocular inflammation in the presence of an A allele at nucleotide-238 and, to a lesser degree, at nucleotide-308 of the TNF-α gene promoter.\cite{25} These findings formed the rationale for using the TNF-α inhibitor biologic agents in HLA-B27-associated ocular inflammatory diseases. Infliximab and adalimumab are the most common TNF-α inhibitor biologic response modifier agents employed in the field of ophthalmology. The successful use of infliximab and adalimumab for controlling ocular and systemic inflammatory conditions has been reported in different studies.\cite{26–31} Adalimumab is the only FDA-approved biologic for the treatment of noninfectious uveitis.\cite{29–31}

The median age (44 years) of our study sample and the prevalence of associated systemic illness (70%) matched earlier studies.\cite{27–31} Infliximab was well-tolerated and BCVA was improved or remained stable in the majority of our patients. Previous studies reported the success of infliximab therapy in different ocular inflammatory diseases with various etiologies including HLA-B27-associated uveitis.\cite{29–32} In two studies by Foeldvari et al and Suhler et al, the success of infliximab in JIA-associated uveitis and panuveitis, intermediate uveitis and posterior uveitis was 70% and 78%, respectively.\cite{28,31} Kim et al and El-shabrawi et al found that infliximab (3–5 mg/kg body weight) was effective in 76.2% and 66.7% of patients with HLA-B27 anterior uveitis.\cite{33,34} In our study, ocular inflammation was controlled in 83.3% of patients at the end of two years; higher than that reported in previous studies.\cite{29,32–34} This can be attributed to adjustment of infliximab dose up to 10 mg/kg based on the response to infliximab therapy.\cite{28,31–33} While previous studies used pulse or oral corticosteroid therapies to control acute inflammation, the aim of our study was to achieve steroid-free remission. Thus, a significant number of our patients were not on steroids for their ocular inflammation at the 24-month follow-up visit. This can be interpreted by the higher doses of infliximab and longer duration of treatment that we employed in our patients.\cite{34,35}

The starting dose for Infliximab therapy was 5 mg/kg in all patients except those with more severe involvement such as retinal vasculitis and scleritis. We followed the protocol of two loading doses and five infusions every four weeks before stretching the infusions. Slow tapering of the infusions has been proved as an effective way to maintain remission in patients on anti-TNF-α inhibitor therapy.\cite{34,36–39} This was also demonstrated in our study. Some of our patients needed to increase the dose of infliximab, which may be due to three possible hypotheses. The first hypothesis is the development of an antibody against the infliximab molecule due to its murine constituent. This may be prevented by adding a low-dose anti-metabolite to the regimen; however, we were unable to make this conclusion due to low sample size. A second possible reason to increase the dose of infliximab is tachyphylaxis to the medication itself. The third mechanism is the lower dose of medication per age in younger individuals due to their growth spurt and an increase in their weight.

In this study, there were two patients with HLA-B27 associated active systemic inflammation and quiet eyes who were started on infliximab by the rheumatologists and their intraocular inflammation occurred early in the course of infliximab therapy. There are two explanations for this finding. First, it might be the natural course of the HLA-B27-associated anterior uveitis, which was not under control with the previous regimen and the time for infliximab to control the inflammation was not sufficient. Second, in our experience, there are some patients with HLA-B27-associated ocular inflammation who need higher doses of infliximab for controlling ocular inflammation. In these patients, ocular inflammation can recur despite their systemic symptoms being controlled with a standard dose of infliximab. That is why the dose adjustment for ocular inflammation control might be necessary after the third infliximab infusion.
Infliximab for HLA-B27 Uveitis; Bajwa and Maleki et al

Our study had the inherent limitations of a retrospective study design with a small sample size. As a tertiary care clinic, a large proportion of our patients present with severe, long-standing, and often unresponsive disease. Moreover, due to the nature of our referral center which has more severe and complicated cases, the trend is toward a more aggressive therapy such as infliximab rather than a less aggressive treatment such as adalimumab injection, and this can also be a source of selection bias. Furthermore, similar to other retrospective studies, the inability to control for confounding factors such as changes in topical, local, and systemic corticosteroids and IMTs for eye and systemic conditions may allow for the development of uveitis early in the course of infliximab therapy.

In summary, Infliximab therapy might be an effective and safe method of treatment for inducing and sustaining the steroid-free remission in patients with HLA-B27-associated ocular inflammation, which can be a serious and potentially blinding condition if left untreated or incompletely treated. However, to validate these findings, more potent studies are required.

Disclosure Statement

Dr. C Stephen Foster declares the following:

Consultancies with Aldeyra Therapeutics (Lexington, MA), Alakos (Redwood City, CA), Bausch & Lomb Surgical, Inc (Rancho Cucamonga, CA), Eyegate Pharma (Waltham, MA), Genentech (South San Francisco, CA), Novartis (Cambridge, MA), pSivida (Watertown, MA). Grants or grants pending with Aciont (Salt Lake City, UT), Alcon (Aliso Viejo, CA), Aldeyra Therapeutics (Lexington, MA), Bausch & Lomb (Rochester, NY), Clearside Biomedical (Alpharetta, GA), Dompe pharmaceutical (Milan, Italy), Eyegate Pharma (Waltham, MA), Mallinckrodt pharmaceuticals (Staines-upon-Thames, UK), Novartis Pharmaceuticals (Cambridge, MA), pSivida (Watertown, MA), Santen (Osaka, Japan).

Payment for lectures including service on speaking bureaus: Alcon (Aliso Viejo, CA), Allergan (Dublin, Ireland), Mallinckrodt pharmaceuticals (Staines-upon-Thames, UK).

Stock or Stock Options: Eyegate Pharma (Waltham, MA)

Other authors have nothing to declare.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author, [CSF], upon reasonable request.

Acknowledgments

Asima Bajva (AB) and Arash Maleki (AM) share first co-authorship as they contributed equally to this manuscript.

Financial Support and Sponsorship

None.

Conflicts of Interest

There are no conflicts of interest.

REFERENCES

1. Chang JH, McCluskey PJ, Wakefield D. Acute anterior uveitis and HLA-B27. Surv Ophthalmol 2005;50:364–388.
2. Ramsay A, Lightman S. Hypopyon uveitis. Surv Ophthalmol 2001;46:1–18.
3. Anshu A, Chee SP. Posterior scleritis and its association with HLA B27 haplotype. Ophthalmologica 2007;221:275–278.
4. Loh AR, Acharya NR. Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis. Am J Ophthalmol 2010;150:534–542.e2.
5. De Vos AF, Klaren VN, Kijlstra A. Expression of multiple cytokines and IL-IRA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 1994;35:3873–3883.
6. Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Patocour E, Méndez-Fernández R, López-Abad C, Matilla M, Garcia-Sanchez J. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (inflimixab). Eye (Lond). 2005 Aug;19(8):841-5. doi: 10.1038/sj.eye.6701689.
7. Lopez-Gonzalez R, Loza E, Jover JA, Benitez Del Castillo JM, Mendez R, Hernandez-Garcia C, et al. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study. Scand J Rheumatol. 2009 Jan-Feb;38(1):58-62. doi: 10.1080/03009740802366076.
8. Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Inflimixab in the treatment of refractory posterior uveitis. Ophthalmology 2003;110:1449–1453.
9. El-Shabrawy Y, Mangge H, Hermann J. Anti-tumour necrosis factor alpha treatment in chronic recurrent inflammation of the anterior segment of the eye in patients resistant to standard immunomodulatory treatment. Ann Rheum Dis 2003;62:1243–1244.
Infliximab for HLA-B27 Uveitis; Bajwa and Maleki et al

10. Suhler EB, Smith JR, Giles TR, Lauer AK, Wertheim MS, Kurz DE, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol. 2009 Jun;127(6):819-22. doi: 10.1001/archophthalmol.2009.141.

11. Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007;125:895–900.

12. El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002;109:2342–2346.

13. Gueudry J, Thorne JE, Bansie R, Braun J, van Hagen PM, Bodaghi B. Biologic therapy for HLA-B27-associated ocular disorders. Ocul Immunol Inflamm 2017;25:169–178.

14. Kim M, Won JY, Choi SY, Ju JH, Park YH. Anti-TNFα treatment for HLA-B27-positive ankylosing spondylitis-related uveitis. Am J Ophthalmol 2016;170:32–40.

15. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 2005;140:509–516.

16. Harper SL, Chorich LJ, Foster CS. Diagnosis of uveitis. In: Foster CS, Vitale AT, editors. Diagnosis and treatment of uveitis. Philadelphia, PA: WB Saunders Co; 2002:79–103.

17. Sen HN, Sangave AA, Goldstein DA, Suhler EB, Cunningham D, Vitale S, et al. A standardized grading system for scleritis. Ophthalmology. 2011 Apr;118(4):768-71. doi: 10.1016/j.ophtha.2010.08.027. Epub 2010 Nov 20.

18. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HLA-27. Lancet 1973;1:904–907.

19. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HLA antigen, W27, with ankylosing spondylitis. N Engl J Med 1973;288:704–706.

20. Pérez-Guillo V, Santos-Lacomba M, Sánchez-Hernández M, Castro-Villegas Mdel C, Gallardo-Galera JM, Collantes-Estevez E. Tumor necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin 2004;20:155–157.

21. De Vos AF, Klaen VN, Kijlstra A. Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 1994;35:3873–3883.

22. Koizumi K, Poukai V, Doehmen S, Welsandt G, Radetzky S, Lappas A, et al. Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest Ophthalmol Vis Sci. 2003 May;44(5):2184-91. doi: 10.1167/iovs.02-0589. Erratum in: Invest Ophthalmol Vis Sci. 2006 Feb;57(2):403.

23. Sartani G, Silver PB, Rizzo LV, Chan CC, Wiggert B, Mastorakos G, et al. Anti-tumor necrosis factor-alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci 1996;37:2211–2218.

24. Mo JS, Matsukawa A, Ohkawara S, Yoshinaga M. Involvement of TNF alpha, IL-1 beta and IL-1 receptor antagonist in LPS-induced rabbit uveitis. Exp Eye Res 1998;66:547–557.

25. El-Shabrawi Y, Wegscheider BJ, Weger M, Renner W, Posch U, Ulrich S, et al. Polymorphisms within the tumor necrosis factor-alpha promoter region in patients with HLA-B27-associated uveitis: association with susceptibility and clinical manifestations. Ophthalmology. 2006 Apr;113(4):695-700. doi: 10.1016/j.ophtha.2006.01.004.

26. Pasadika S, Suhler E, Emmett Jr C. Use of biologic agents in the treatment of uveitis. Rev Ophthalmol Retin Insid 2010. Available from: http://www.reviewofophthalmology.com/content/d RETIN_INSID/1208/c/22770/ (accessed Nov 5, 2013).

27. Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 2005;43:7–11.

28. Matsuda J, Kaburaki T, Kobayashi S, Numaqa J. Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis. Jpn J Ophthalmol 2013;57:104–107.

29. Foeldvari I, Nielsen S, Kummerie-Deschner J, Espada G, Horneff G, Bica B, et al. Tumor necrosis factor alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol. 2007 May;34(5):1146-50. Epub 2007 Mar 1.

30. Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016 Sep 17;388(10050):1183-92. doi: 10.1016/S0140-6736(16)31339-3. Epub 2016 Aug 16. Erratum in: Lancet. 2016 Sep 17;388(10050):1160.

31. Suhler EB, Adán A, Brézin AP, Fortin E, Goto H, Jaffe GJ, et al. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Ophthalmology. 2018 Jul;125(7):1075-1087. doi: 10.1016/j.jophtha.2017.06.039.

32. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903–912.

33. Kim M, Won JY, Choi SY, Ju JH, Park YH. Anti-TNFα treatment for HLA-B27-positive Ankylosing spondylitis-related uveitis. Am J Ophthalmol 2016;170:32–40.

34. El-shabrawi W, Hermann J. Case series of selective anti-tumor necrosis factor alpha therapy using infliximab in patients with nonresponsive chronic HLA-B27-associated anterior uveitis: comment on the articles by Brandt et al. Arthritis Rheum 2002;46:2821–2822.

35. Paccou J, Baclé-Boutry M-A, Solau-Gervais E, Bele-Philippe P, Flipo RM. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice. J Rheumatol 2012;39:1418–1423.

36. Richards JC, Tay-Kearney M-L, Murray K, Manners GA, Novak SI, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903–912.

37. Kim M, Won JY, Choi SY, Ju JH, Park YH. Anti-TNFα treatment for HLA-B27-positive Ankylosing spondylitis-related uveitis. Am J Ophthalmol 2016;170:32–40.

38. El-shabrawi W, Hermann J. Case series of selective anti-tumor necrosis factor alpha therapy using infliximab in patients with nonresponsive chronic HLA-B27-associated anterior uveitis: comment on the articles by Brandt et al. Arthritis Rheum 2002;46:2821-2822.

39. Paccou J, Baclé-Boutry M-A, Solau-Gervais E, Bele-Philippe P, Flipo RM. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice. J Rheumatol 2012;39:1418-1423.

40. Richards JC, Tay-Kearney M-L, Murray K, Manners GA, Novak SI, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-912.

41. Kim M, Won JY, Choi SY, Ju JH, Park YH. Anti-TNFα treatment for HLA-B27-positive Ankylosing spondylitis-related uveitis. Am J Ophthalmol 2016;170:32-40.

42. El-shabrawi W, Hermann J. Case series of selective anti-tumor necrosis factor alpha therapy using infliximab in patients with nonresponsive chronic HLA-B27-associated anterior uveitis: comment on the articles by Brandt et al. Arthritis Rheum 2002;46:2821-2822.
39. Petropoulos IK, Vaudaux JD, Guex-Crosier Y. Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital. *Klin Monbl Augenheilkd* 2008;225:457–461.